Keyphrases
Capsaicin
59%
Ultraviolet-B (UV-B)
50%
Experimental Pain
50%
Mathematical Model Analysis
50%
Sodium Channel Blocker
50%
Dibenzoxazepine
50%
Dibenzazepine
50%
Hyperthermia Induced
50%
TRPV1 Antagonist
50%
Celecoxib
50%
Randomized Double-blind
50%
3-way
50%
Human Trials
50%
Meta-analysis
50%
Healthy Volunteers
50%
Pain Research
50%
Transient Receptor Potential Vanilloid 1 (TRPV1)
50%
Body Temperature
46%
Placebo
37%
COX-2 Inhibitors
25%
Heat Pain
25%
Tolerance Limits
25%
Pain Detection
25%
Antihyperalgesic
25%
Nav1.7
25%
FLIPR
25%
Pain Tolerance
25%
Stimuli-responsiveness
25%
Response Function
25%
Detection Threshold
25%
Hyperalgesia
25%
Functional Assay
25%
Proton
15%
Laser Doppler Flowmetry
12%
Oral Treatment
12%
Von Frey
12%
Heat Pain Threshold
12%
Clinical Targets
12%
Erythema Index
12%
Pressure Pain
12%
Pain Threshold
12%
Pain Sensitivity
12%
Rat Model
12%
3' End
12%
Single Center
12%
Hyperthermia
12%
Safety Issues
12%
Analgesia
12%
Neurogenic Inflammation
12%
Treatment Duration
12%
Pharmacology, Toxicology and Pharmaceutical Science
Vanilloid Receptor 1 Antagonist
100%
Capsaicin
66%
Vanilloid Receptor 1
50%
Dibenzoxazepine Derivative
50%
Dibenzazepine Derivative
50%
Sodium Channel Blocking Agent
50%
Experimental Pain
50%
Celecoxib
50%
Normal Human
50%
Clinical Trial
50%
Hyperthermia
50%
Placebo
37%
Dibenzazepine
25%
COX-2 Inhibitor
25%
Hyperalgesia
25%
Hypothermia
16%
Rat Model
12%
Neurogenic Inflammation
12%
Erethism
12%
Side Effect
12%
Erythema
12%
Experimental Animal
5%
Medicine and Dentistry
Experimental Pain
50%
Vanilloid Receptor 1 Antagonist
50%
Celecoxib
50%
Capsaicin
50%
Volunteer
50%
Placebo
37%
Stimulus Response
25%
Cyclooxygenase 2 Inhibitor
25%
Hyperpathia
25%
Laser Doppler Flowmetry
12%
Pressure Pain Threshold
12%
Heat Pain Threshold
12%
Neurogenic Inflammation
12%
Analgesia
12%
Erythema
12%
Hypersensitivity
12%
Sensitization
12%
Single Drug Dose
12%
Side Effect
12%